| 词条 | Gadoteric acid |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 407376289 | IUPAC_name = gadolinium(+3) cation; 2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate | image = Gadoteric acid.png | tradename = | Drugs.com = {{drugs.com|international|gadoteric-acid}} | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 72573-82-1 | ATC_prefix = V08 | ATC_suffix = CA02 | PubChem = 3085828 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | UNII_Ref = {{fdacite|changed|FDA}} | UNII = QVF9Y6955W | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D08007 | C=16 | H=25 | Gd=1 | N=4 | O=8 | molecular_weight = 558.64 g/mol }}Gadoteric acid (gadoterate meglumine, trade names Artirem, Dotarem and Clariscan) is a macrocycle-structured gadolinium-based MRI contrast agent (GBCA). It consists of the organic acid DOTA as a chelating agent, and gadolinium (Gd3+), and is used in form of the meglumine salt (Gadoterate meglumine).[1] The paramagnetic property of gadoteric acid reduces the T1 relaxation time (and to some extent the T2 and T2* relaxation times) in MRI, which is the source of its clinical utility. Because it has magnetic properties, gadoteric acid develops a magnetic moment when put under a magnetic field, which increases the signal intensity (brightness) of tissues during MRI imaging.[2] UsageIt is used for imaging of blood vessels and inflamed or diseased tissue where the blood vessels become 'leaky'. It is often used when viewing intracranial lesions with abnormal vascularity or abnormalities in the blood–brain barrier. Gadoteric acid is used for MRI imaging of the brain, spine, and associated tissues for adult and pediatric (2 years of age or older) patients. The meglumine salt it takes the form of crosses the blood brain barrier of tissue with abnormal vasculature, highlighting the affected area with MRI. Gadoterate does not cross the intact blood-brain barrier, so it does not affect or enhance normal brain tissue in imaging.[1] Dotarem is administered through an intravenous bolus injection, either manually or through a power injection.[2] Adverse effectsThe most common adverse effects (>0.2%) in clinical studies were nausea, headache, injection site pain, injection site coldness, and burning sensation. Drugs with gadolinium-based contrasting agents can increase the risk of nephrogenic systemic fibrosis (NSF) for those with impaired elimination of the drug. Those most at risk for NSF include patients with chronic or severe kidney disease and acute kidney injury.[2][3] AvailabilityThe drug, under the brand Dotarem, was brought to market by Guerbet.[7] As of 2013 gadoteric acid was approved in around 70 countries.[4][5] It was launched in the French market in 1989 and was FDA approved in the US in March, 2013.[6] Dotarem is the seventh FDA approved GBCA for use in central nervous system (CNS) MRI. In 2017, GE Healthcare launched a gadoteric acid (as gadoterate meglumine) under the trade name Clariscan[7] Other FDA approved GBCAs for similar purposes include Magnevist (1988), Prohance (1992), Omniscan (1993), Optimark (1999), Multihance (2004) and Gadavist (2011).[8] References1. ^1 {{Cite journal|date=2016-08-22|editor-last=DrugBank|title=Gadoteric acid|url=http://www.drugbank.ca/drugs/DB09132|journal=DrugBank}} {{Contrast media}}2. ^1 2 {{cite web|title=US gadoterate meglumine label|url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204781s000lbl.pdf|publisher=FDA|date=March 2013}} 3. ^{{cite journal|last1=Todd|first1=DJ|last2=Kay|first2=J|title=Gadolinium-Induced Fibrosis.|journal=Annual Review of Medicine|date=2016|volume=67|pages=273–91|pmid=26768242|doi=10.1146/annurev-med-063014-124936}} 4. ^{{cite web|title=Gadoteric Acid international brands|url=https://www.drugs.com/international/gadoteric-acid.html|publisher=Drugs.com|accessdate=7 March 2017}} 5. ^{{cite web|last1=Guerbet LLC|title=Advisory Committee Briefing Document for NDA 204-781|url=https://www.fda.gov/downloads/AdvisoryCommittees/UCM339378|publisher=FDA|date=14 February 2013}} 6. ^1 {{cite news|last1=Hollmer|first1=Mark|title=Dotarem: A safe(r) gadolinium-based contrast imaging agent|url=http://www.fiercebiotech.com/special-report/dotarem-a-safe-r-gadolinium-based-contrast-imaging-agent|work=FierceBiotech|date=January 6, 2014}} 7. ^http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1487912585095.pdf 8. ^{{Cite web|url=http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm344758.htm|title=Press Announcements - FDA approves Dotarem, a new magnetic resonance imaging agent|website=www.fda.gov|language=en|access-date=2016-11-14}} 2 : Gadolinium compounds|MRI contrast agents |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。